Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Peter J. Hamer"'
Autor:
Suhail M. Ali, Syed Rizvi, R Kalu, V Shrinvastava, A. Lipton, K Repich, Matt Evans, Sheryl Brown-Shimer, Peter J. Hamer, E-M Fuchs, U. Anyanwu, Kim Leitzel, Jessica Ramirez, W. Koestler, H. Y. Hou, Walter P. Carney
Publikováno v:
Cancer Research. 70:P2-09
Background: Approximately one-half of HER2-positive breast cancer patients will respond to first-line trastuzumab-containing therapy. However, in those patients with an initial trastuzumab response, most will progress within a year with acquired resi
Autor:
Kim Leitzel, Karen Pierce, H. A. Chaudri-Ross, Allan Lipton, Dean B. Evans, Laurence M. Demers, Suhail M. Ali, Victor Gaur, Peter J. Hamer, Sheryl Brown-Shimer, Walter P. Carney
Publikováno v:
Journal of Clinical Oncology. 26:2653-2658
PurposeTo determine the effect of elevated serum TIMP-1 on the response of patients with metastatic breast cancer to an aromatase inhibitor versus tamoxifen.Patients and MethodsFive hundred twenty-two patients estrogen receptor–positive metastatic
Autor:
Susanna Jacobus, Karen Pierce, Sheryl Brown-Shimer, Allan Lipton, Roberto Vargas, Peter J. Hamer, Walter P. Carney, Philip W. Kantoff, Kim Leitzel, Meredith M. Regan, William Oh, Suhail M. Ali
Publikováno v:
Cancer. 117(3)
Tissue inhibitor of metalloproteinase-1 (TIMP-1) has paradoxical multifunctional roles in tumorigenesis: inhibition of the catalytic activity of matrix metalloproteinases and apoptosis as well as promotion of angiogenesis and tumor growth. Elevated T
Autor:
Efstathios Kastritis, Dimitrios Christoulas, Maria Gavriatopoulou, Kim Leitzel, Evangelos Terpos, Konstantinos Anargyrou, Meletios A. Dimopoulos, Vikas Shrivastava, Magdalini Migkou, Peter J. Hamer, Walter P. Carney, Allan Lipton
Publikováno v:
Leukemia research. 34(3)
Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorp
Autor:
Kevin L. Trimpe, Mariano Barbacid, Joyce A. Lavecchio, Walter P. Carney, David S. Garlick, Saraswati Sukumar, Irwin Leav, Peter J. Hamer, Debra Ann Petit
Publikováno v:
Hybridoma. 10:95-102
ras genes have been shown to become oncogenes by single point mutations which result in amino acid substitutions that affect either their GTPase activity (positions 12, 13, 59, 61) or their affinity for GTP and GDP. Ras oncogenes and their correspond
Autor:
Peter J. Hamer, Kim Leitzel, Karen Pierce, Allan Lipton, Suhail M. Ali, Dean B. Evans, Laurence M. Demers, Walter P. Carney, Sheryl Brown-Shimer
Publikováno v:
Cancer. 109(10)
BACKGROUND. Tissue inhibitors of metalloproteinase (TIMPs) have at least 2 different functions. They inhibit the catalytic activity of matrix metalloproteinases, and they act as growth factors. METHODS. Pretreatment ethylenediamine tetracetic acid pl
Autor:
Kim Leitzel, Wolfgang Hackl, Laurence M. Demers, H. A. Chaudri-Ross, Suhail M. Ali, Peter J. Hamer, Walter P. Carney, Dean B. Evans, Allan Lipton, Christopher Souder
Publikováno v:
Cancer. 107(10)
BACKGROUND. Epidermal growth factor receptor (EGFR, HER-1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme-linked imm
Autor:
Peter J. Hamer, E. Fuchs, Kim Leitzel, Matthew S. Evans, Suhail M. Ali, W. Koestler, Walter P. Carney, H. Y. Hou, Sheryl Brown-Shimer, Allan Lipton, U. Anyanwu
Publikováno v:
Cancer Research. 71:2276-2276
Background: About half of HER2-positive breast cancer patients will respond to first-line trastuzumab-containing therapy, but of these most will progress within a year with acquired resistance. Since trastuzumab treatment is now used in the HER2-posi
Publikováno v:
Journal of Clinical Oncology. 28:e21093-e21093
e21093 Background: NSCLC accounts for ∼80% of all lung cancer cases. Five-year survival rates for stage IV disease are very poor compared with stage I (2% vs. 56%). Therefore, tools are needed to a...
Autor:
Walter P. Carney, A. Lipton, Kim Leitzel, Peter J. Hamer, U. Anyanwu, N. Jamshidi, E. Fuchs, H. Y. Hou, Wolfgang J. Köstler, Suhail M. Ali
Publikováno v:
Journal of Clinical Oncology. 28:1050-1050
1050 Background: About half of patients with HER2-positive breast cancer will respond to first-line trastuzumab-containing therapy, but of these most will progress within a year with acquired resis...